TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of MBC-11 in Patients With CIBD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed malignant tumor (breast cancer, prostate cancer etc)~* Bone metastases, documented by radiographs, bone scan~* No available standard chemotherapy or no indication for chemotherapy at the time of screening~* Eastern Cooperative Oncology Group \[ECOG\] status 0-2~* Adequate bone marrow function (hemoglobin ≥ 9 g/dL with or without transfusion requirement, absolute neutrophil count ≥ 1500/mm3, and platelets ≥ 75,000/mm3)~* Adequate liver function (bilirubin ≤ 2 x Upper Limit of Normal \[ULN\], Alanine aminotransferase \[ALT\] ≤ 2.5 x ULN).~* Adequate renal function (creatinine ≤ 1.5 x ULN) and creatinine clearance ≥ 50 mL/min \[measured or calculated by nomogram\]).~Exclusion Criteria:~* Systemic chemotherapy and/or investigational therapy within the previous 4 weeks~* Fracture ≤ 6 month prior the inclusion in the study~* Brain metastasis~* Serum calcium levels \< 8.5 mg/dL (\< 2.2 mmol/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dose escalation of MBC-11 (Type: EXPERIMENTAL): MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adequate WBC~* adequate liver and kidney function~* no immunodeficiency~* ECOG \< 2~Exclusion Criteria:~* advanced liver cirrhosis~* severe cardiopulmonary diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Medication Prazosin for Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current primary DSM-IV diagnosis of alcohol dependence(AD)~* Heavy drinking in the last 30 days~* At least 18 years of age~* Good general medical health (see Exclusion Criteria below)~* Capacity to provide informed consent~* English fluency and literacy~Exclusion Criteria:~* Psychiatric/behavioral: current post-traumatic stress disorder(PTSD); psychiatric disorder requiring any medication other than anti-depressants; currently taking disulfiram, acamprosate, or naltrexone or planning to take any of these medications during the 12-week medication phase of the study; current dependence on any other psychoactive substance other than nicotine or cannabis; a current diagnosis of opioid abuse, use of any opioid- containing medications or benzodiazepines during the previous month, or UDA positive for opioids, benzodiazepines, or sedative hypnotics.~* Medical: significant acute or chronic medical illness; women who are pregnant, nursing infant(s), or of childbearing potential and not using a contraceptive method judged by the study physician or PA to be effective; signs or symptoms of alcohol withdrawal at the time of initial consent~* Legal involvement that could interfere with study treatment. Individuals court ordered for treatment will not be eligible to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 - Prazosin Medication (Type: EXPERIMENTAL): Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
- 2 - Placebo Medication (Type: PLACEBO_COMPARATOR): Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study.~2. Male and female 18 years of age and older.~3. Participants must have clinical diagnosis of moderate to severe rosacea.~4. Have a minimum total of 15 and a maximum of 70 total inflammatory lesions (papules and/or pustules) including those present on the nose.~5. Have 2 nodules or less.~Exclusion Criteria:~1. Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at Baseline or screening visits.~2. Presence of more than 2 facial nodules or any nodule greater than 1 centimeter (cm).~3. Current or past ocular rosacea (for example, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S5G4T-1 (Type: EXPERIMENTAL): Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
- S5G4T-2 Vehicle Cream (Type: PLACEBO_COMPARATOR): Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Better Evidence for Selecting Transplant Fluids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult or child with End-Stage Kidney Disease, of any cause, on maintenance dialysis, or who has pre-dialysis stage 5 chronic kidney disease with an estimated Glomerular Filtration Rate of \<15 mL/min/1.73m2, AND~2. Planned deceased donor kidney transplant from a brain-death (DBD) or circulatory-death (DCD) organ donor within 24 hours, AND~3. Written informed consent, or consent given by their parent or guardian (if age \<18), or other authorised person~Exclusion Criteria:~1. Planned live donor kidney transplant (except where this is cancelled in favour or transplantation from a deceased donor)~2. Planned multi-organ transplant (dual or en-bloc kidney transplants are not excluded)~3. Children of weight \<20 kg, or a child that the treating physician believes should not be included in a study of blinded fluids due to their small body size~4. Known hypersensitivity to the trial fluid preparations or packaging

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasma-Lyte 148 (approx. pH 7.4) IV Infusion (Type: EXPERIMENTAL): Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
- 0.9% SODIUM CHLORIDE 9g/L injection BP (Type: ACTIVE_COMPARATOR): 0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with congenital heart disease undergoing cardiac surgery~* intraoperative aortic cross clamp over 90 minutes or interventional catheterization procedures with post-operative inotrope score over 20~* sign of fluid retention after surgical procedures~Exclusion Criteria:~* Preoperative renal dysfunction~* Preoperative administration of more than 4mg/kg/die loop diuretics~* Need for renal replacement therapy at ICU admission~* Need for ECMO at ICU admission

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- furosemide (Type: ACTIVE_COMPARATOR): furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
- ethacryinic acid (Type: ACTIVE_COMPARATOR): ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed the Treatment and Transition Period of EP0008 \[NCT01710657\]~Exclusion Criteria:~* Subjects who withdrew from EP0008 \[NCT01710657\]

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Lacosamide treatment of 100 - 400 mg/day for long-term

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic hepatitis C, genotype 1;~* treatment-naive.~Exclusion Criteria:~* liver cirrhosis and other forms of liver disease;~* HIV infection;~* hepatocellular cancer;~* cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Placebo in combination with standard doses of Pegasys and Copegus.
- Part 1: RO5190591 300mg po (Type: EXPERIMENTAL): RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
- Part 1: RO5190591 600mg po (Type: EXPERIMENTAL): RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
- Part 1: RO5190591 900mg po (Type: EXPERIMENTAL): RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
- Part 2: RO5190591 300mg po (Type: EXPERIMENTAL): If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* in good health~* body mass index of 20 to 29.9 kg/m2~* female subjects must be either postmenopausal for at least 1 year, surgically sterile, abstinent, or agree to use an effective method of birth control~Exclusion Criteria:~* history or clinical manifestations of any clinically significant disorder~* history of hypersensitivity or allergies to any drug compound~* history of stomach or intestinal surgery or resection~* history of alcoholism or drug addiction within 1 year~* use of any tobacco-containing or nicotine-containing products within 6 months~* use of any other medications~* use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages; or foods or beverages with high levels of tyramine~* pregnancy, lactation, or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
- 2 (Type: PLACEBO_COMPARATOR): Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
- 3 (Type: ACTIVE_COMPARATOR): Oral doses of 600mg linezolid given twice daily for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Heel Offloading Devices for Reducing Heel Contact Pressures in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* No musculoskeletal injury in the past month~* Body Mass Index (BMI) between 18.5 and 39.9~Exclusion Criteria:~* 17 years old or younger~* Musculoskeletal injury in the past month~* Pregnant or lactating female~* History of heel pressure ulceration~* BMI below 18.5 or above 39.9

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Pressure mapping is performed without a heel offloading intervention applied.
- Pillow Condition 1 (Type: EXPERIMENTAL): Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
- Pillow Condition 2 (Type: EXPERIMENTAL): Pressure mapping is performed with the Pillow condition 2 applied to the heel.
- Heel Foam Pillow (Type: EXPERIMENTAL): Pressure mapping is performed with the heel foam pillow device applied to the heel.
- Offloading Device A (Type: EXPERIMENTAL): Pressure mapping is performed with Offloading Device A applied to the heel.
- Offloading Device B (Type: EXPERIMENTAL): Pressure mapping is performed with Offloading Device B applied to the heel.
- Offloading Device C (Type: EXPERIMENTAL): Pressure mapping is performed with Offloading Device C applied to the heel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allergy Immunotherapy for the Reduction of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 18 months through 3 years who had at least 2 episodes of wheezing prior to enrolment.~* Positive skin tests or specific Immunoglobulin E (IgE) antibody titers to at least one of common airborne allergens: Dust Mite, cat, cockroach, mouse, dog, pollen (all allergy testing can be done at the screening visit at the study site).~* The child must also fulfill the criteria for high risk of developing persistent asthma by meeting at least one of the following major conditions OR 2 of the following minor conditions:~  * Major criteria: History of atopic dermatitis and/or parental history of asthma.~ * Minor criteria: MD-diagnosed allergic rhinitis, wheezing unrelated to colds, blood eosinophils above 4%.~Exclusion Criteria:~* The child has a severe systemic condition (other than allergy or asthma) including (but not limited to) seizures, major congenital anomalies, physical and intellectual delay, cerebral palsy, chest surgery, tuberculosis, primary or secondary immunodeficiency or cardiac disorder (except a hemodynamically insignificant atrial or ventricular septum defect or heart murmur).~* The child was born following 35 or less weeks of gestation.~* Parental report that the child received oxygen for more than 5 days in the neonatal period, or required mechanical ventilation at any time since birth.~* The child fails to thrive, defined as crossing of two major growth percentile lines during the last year.~* The child has chronic lung disease of prematurity (CLDP), cystic fibrosis or any other chronic lung disease.~* The child ever received immunotherapy.~* The child ever received i.v. gammaglobulins or immunosuppressants (other than corticosteroids for asthma).~* History of a life-threatening asthma exacerbation which required intubation and mechanical ventilation.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- No immunotherapy, receive standard of care asthma treatment (Type: ACTIVE_COMPARATOR): This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
- Allergen immunotherapy (Type: EXPERIMENTAL): This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin in Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Men or women aged 18 to 85 years Spontaneous pain with a minimal intensity of 4/10 on numerical scle Pain present for at least 6 months Pain related to painful mononeuropathy or sensory polyneuropathy Able to understand the protocol and comply to the requirements of the study Written informed consent Painful area limited to a maximum of 240 cm2~Exclusion Criteria:~Facial pain Litigation (pending) Unstable condition responsible for neuropathic pain (ie, unstable immunological disease...) HIV or chemotherapy induced neuropathy Contraindications to BTX-A (neuromuscular disease, hypersensitivity, infection, coagulation disorder, pregnancy) Other pain more severe than neuropathic pain No compliance with the self diary Drug abuse or alcoholism Severe major depression Cognitive impairment Other research protocol within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- botulinum toxin type A (Type: ACTIVE_COMPARATOR): botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)
- sodium chloride 9 % (Type: PLACEBO_COMPARATOR): sodium chloride 9 % will be used as a neutral placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Stem Cells in Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with knee osteoarthritis grade II or III of the Kellgren-Lawrence radiographic scale~* Age \> 30 years~Exclusion Criteria:~* Neurodegenerative, autoimmune, genetic or psychiatric diseases~* Active infection~* Recent joint infection~* Knee surgery history~* Knee joint fracture history

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Patients treated with Acetaminophen
- Experimental (Type: EXPERIMENTAL): Patients who underwent a BMASC extraction and joint infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete